Selective plasmosorption of extracellular DNA and NETs in patients with difficult-to-treat rheumatoid arthritis (first clinical experience)
E. A. Aseeva,
E. A. Pletnev,
N. S. Pokrovsky,
S. K. Soloviev,
E. V. Nikolaeva,
N. Yu. Nikishina,
E. T. Abdullin,
L. M. Blank,
E. G. Zotkin,
A. M. Lila https://doi.org/10.14412/1996-7012-2025-5-98-105
Abstract
Rheumatoid arthritis (RA) associated with interstitial lung disease (RA-ILD) represents a distinct clinical and pathogenetic phenotype characterized by high inflammatory activity, seropositivity, and systemic manifestations. In recent years, increasing attention has been directed to the role of extracellular DNA and neutrophil extracellular traps (NETs) in RA pathogenesis. This report presents the first case of selective plasmosorption of extracellular DNA and NETs in a patient with RA-ILD. The therapy was associated with a decrease in joint pain and stiffness and improvement of general condition. Laboratory parameters were also monitored dynamically. This clinical case demonstrates the potential of DNA-containing structure plasmosorption as an adjunctive method to enhance the effect of therapy with biological disease modifying antirheumatic drugs in refractory RA.
Keywords
rheumatoid arthritis,
extracorporeal therapy,
neutrophil extracellular traps,
extracellular DNA,
therapeutic apheresis
Supporting agencies: The article was prepared within the framework of the state assignment № PK 125020501434-1 “Investigation of immunopathology and approaches to therapy in systemic rheumatic diseases.”
About the Authors
E. A. Aseeva
V.A, Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Elena Alexandrovna Aseeva
34A, Kashirskoe Shosse, Moscow 115522
E. A. Pletnev
V.A, Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
N. S. Pokrovsky
National Medical Research Centre of Cardiology named after Academician E.I. Chazov, Ministry of Health of Russia
Russian Federation
Russian Federation
15A, Akademika Chazova Street, Moscow 121552
S. K. Soloviev
V.A, Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. V. Nikolaeva
V.A, Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
N. Yu. Nikishina
V.A, Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. T. Abdullin
National Medical Research Centre of Cardiology named after Academician E.I. Chazov, Ministry of Health of Russia ; Lomonosov Moscow State University
Russian Federation
Russian Federation
15A, Akademika Chazova Street, Moscow 121552
1, Leninskie Gory, Moscow 119991
L. M. Blank
V.A, Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. G. Zotkin
V.A, Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. M. Lila
V.A, Nasonova Research Institute of Rheumatology ; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
References
1. Nasonov EL, Lila AM. Rheumatoid arthritis: achievements and unresolved issues. Terapevticheskii arkhiv. 2019;91(5): 4-7. (In Russ.).
2. Nasonov EL, Ananyeva LP, Avdeev SN. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Nauchno-Prakticheskaya Revmatologia. 2022;60(6):517-534. (In Russ.).
3. Nasonov EL. Problems of rheumatoid arthritis immunopathology: evolution of the disease. Rheumatology Science and Practice. 2017;55(3):277-294. (In Russ.).
4. Catrina A, Krishnamurthy A, Rethi B. Current view on the pathogenic role of anticitrullinated protein antibodies in rheumatoid arthritis. RMD Open. 2021 Mar;7(1):e001228. doi: 10.1136/rmdopen-2020-001228.
5. Mutua V, Gershwin LJ. A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics. Clin Rev Allergy Immunol. 2021 Oct;61(2):194-211. doi: 10.1007/s12016-020-08804-7.
6. Avdeeva AS, Aleksankin AP. NETosis: assessment methods and role in the pathogenesis of systemic autoimmune rheumatic diseases (review of literature). Klinicheskaya laboratornaya diagnostika. 2024;69(5):206-214. (In Russ.).
7. Foulquier C, Sebbag M, Clavel C, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 2007 Nov;56(11): 3541-53. doi: 10.1002/art.22983.
8. Nasonov EL, Avdeeva AS, Reshetnyak TM, et al. The role of NETosis in the pathogenesis of immunoinflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia. 2023; 61(5):513-530. (In Russ.).
9. Carmona-Rivera C, Carlucci PM, Goel RR, et al. Neutrophil extracellular traps mediate articular cartilage damage and enhance cartilage component immunogenicity in rheumatoid arthritis. JCI Insight. 2020 Jul 9;5(13): e139388. doi: 10.1172/jci.insight.139388.
10. Schneider AH, Taira TM, Publio GA, et al. Neutrophil extracellular traps mediate bone erosion in rheumatoid arthritis by enhancing RANKL-induced osteoclastogenesis. Br J Pharmacol. 2024 Feb;181(3):429-446. doi: 10.1111/bph.16227.
11. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013 Mar 27;5(178): 178ra40. doi: 10.1126/scitranslmed.3005580.
12. Carmona-Rivera C, Carlucci PM, Moore E, et al. Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. Sci Immunol. 2017 Apr;2(10):eaag3358. doi: 10.1126/sciimmunol.aag3358.
13. Jarzebska N, Rodionov RN, Voit-Bak K, et al. Neutrophil Extracellular Traps (NETs) as a Potential Target for Anti-Aging: Role of Therapeutic Apheresis. Horm Metab Res. 2025 Jan 9. doi: 10.1055/a-2444-3422. Online ahead of print.
14. Sur Chowdhury C, Giaglis S, Walker UA, et al. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: Analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 2014 Jun 13;16(3):R122. doi: 10.1186/ar4579.
15. Gordeev AV, Olyunin YA, Galushko EA, et al. Difficult-to-treat rheumatoid arthritis. What is it? Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(5):7-11. doi: 10.14412/1996-7012-2021-5-7-11
16. Xie S, Li S, Chen B, et al. Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis-related interstitial lung disease: A metaanalysis. Clin Rheumatol. 2021 Nov;40(11): 4533-4543. doi: 10.1007/s10067-021-05808-2.
17. Sparks JA, He X, Huang J, et al. Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritisassociated interstitial lung disease: A prospective cohort study. Arthritis Rheumatol. 2019 Sep;71(9):1472-1482. doi: 10.1002/art.40904.
18. Kelly C, Emery P, Dieude P. Current issues in rheumatoid arthritis related interstitial lung disease (RA-ILD). Lancet Rheum. 2021; 3(11):e798-e807. doi: 10.1016/S2665-9913(21)00250-2
19. Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. 2022 May;21(5): 103056. doi: 10.1016/j.autrev.2022.103056.
20. Yu KH, Chen HH, Cheng TT, Jan YJ, Weng MY, Lin YJ, et al. Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore). 2022;101(1):e28501. doi: 10.1097/MD.0000000000028501 92.
21. Diesler R, Cottin V. Pulmonary fibrosis associated with rheumatoid arthritis: From pathophysiology to treatment strategies. Expert Rev Respir Med. 2022 May;16(5):541-553. doi: 10.1080/17476348.2022.2089116.
22. Roodenrijs NMT, Hamar A, Kedves M, et al. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: A systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021 Jan;7 (1):e001512. doi: 10.1136/rmdopen-2020-001512.
23. Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021 Jan;17(1):17-33. doi: 10.1038/s41584-020-00541-7.
24. Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: The problems of remission and therapy resistance. Nauchno-Prakticheskaya Revmatologia. 2018;56(3): 263-271. (In Russ.).
25. Solov'ev SK, Aseeva EA, Chiklikchi AS, Lashina NYu. Synchronic intensive program therapy of patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia. 2000; 38(1):49-54. (In Russ.).
26. Xing Y, Wang S, Liu C, et al. Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatod arthritis: A retrospective cohort study. Medicine (Baltimore). 2020 Jul 10;99(28): e20966. doi: 10.1097/MD.0000000000020966.
27. Yu X, Zhang L, Wang L, et al. MRI assessment of erosion repair in patients with longstanding rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial. Clin Rheumatol. 2018 Apr; 37(4):917-925. doi: 10.1007/s10067-017-3956-3.
28. Yu X, Ma J, Tian J, et al. A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis. J Clin Rheumatol. 2007 Aug;13(4):193-8. doi: 10.1097/RHU.0b013e318124a483.
29. Aseeva EA, Pokrovskii NS, Solov'ev SK, et al. The first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2024;18(2): 75-80. (In Russ.). doi: 10.14412/1996-7012-2024-2-75-80
30. Mena-Vazquez N, Redondo-Rodriguez R, Rojas-Gimenez M, et al. Efficacy and safety of rituximab in autoimmune disease-associated interstitial lung disease: A prospective cohort study. J Clin Med. 2022 Feb 10;11(4):927. doi: 10.3390/jcm11040927.
31. Matteson E, Bongartz T, Ryu J, et al. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis. 2012;2(3):53-58. doi: 10.4236/ojra.2012.23011
32. Vadillo C, Nieto MA, Romero-Bueno F, et al. Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: Data from the NEREA Registry. Rheumatology (Oxford). 2020 Aug 1; 59(8):2099-2108. doi: 10.1093/rheumatology/kez673.
Review
For citations:
Aseeva EA, Pletnev EA, Pokrovsky NS, Soloviev SK, Nikolaeva EV, Nikishina NY, Abdullin ET, Blank LM, Zotkin EG, Lila AM. Selective plasmosorption of extracellular DNA and NETs in patients with difficult-to-treat rheumatoid arthritis (first clinical experience). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(5):98-105. (In Russ.) https://doi.org/10.14412/1996-7012-2025-5-98-105
Views:
35
Email this article 